This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Remission of Panic Disorder With Mirtazapine Augmentation of Paroxetine: A Case Report

Zoran Milan Pavlovic, MD

Published: October 15, 2007

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Paroxetine is a selective serotonin reuptake inhibitor(SSRI) antidepressant with proven efficacy in the short- andlong-term treatment of panic attacks with or without agoraphobia.1 Mirtazapine is a noradrenergic and specific serotonergicantidepressant that acts by antagonizing the adrenergic α2-autoreceptorsand α2-heteroreceptors, as well as by blocking serotonin5-HT2 and 5-HT3 receptors. It enhances, therefore, therelease of norepinephrine and 5-HT1A-mediated serotonergictransmission.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 9

Quick Links: